-
Regulatory April 8, 2025Notice of Annual General Meeting in Vivesto AB
-
Non Regulatory April 1, 2025Vivesto reports positive Cantrixil results in an animal hematological cancer model
-
Regulatory March 31, 2025Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights
Vivesto published its annual report for 2024 on April 8, 2025, at 08.00 am CET.